Malignant mesothelioma: Current status and perspective in Japan and the world

General Thoracic and Cardiovascular Surgery

Volumn 56, Issue 7, 2008, Pages 317-323

  Hasegawa, Seiki ^a   Tanaka, Fumihiro ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Extrapleural pneumonectomy; Malignant pleural mesothelioma; Multimodality treatment; Pleurectomy

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; HYALURONIC ACID; PEMETREXED;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; INCIDENCE; JAPAN; LAPAROSCOPY; LUNG RESECTION; MALIGNANT MESOTHELIOMA; MEDIASTINOSCOPY; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA MESOTHELIOMA; PLEURECTOMY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SURVIVAL RATE; THORACOSCOPY; THORAX RADIOGRAPHY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HUMANS; JAPAN; LAPAROSCOPY; MEDIASTINOSCOPY; MESOTHELIOMA; NEOPLASM STAGING; PLEURAL NEOPLASMS; PNEUMONECTOMY; RADIOTHERAPY, ADJUVANT; THORACIC SURGICAL PROCEDURES; THORACOSCOPY; TREATMENT OUTCOME;

EID: 46749124319     PISSN: 18636705     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11748-007-0243-2     Document Type: Review

References (60)

1. Ceresoli GL, Locati LD, Ferreri AJ, Cozzarini C, Passoni P, Melloni G, et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 2001;34:279-287.
2. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007;62(suppl 2):1-19.
3. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
4. Murayama T, Takahashi K, Natori Y, Kurumatani N. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med 2006;49:1-7.
5. Nakano T, Chahinian AP, Shinjo M, Tonomura A, Miyake M, Togawa N, et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 1998;77:907-912.
6. Leung AN, Muller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol 1990;154:487-492.
7. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997;111:106-109.
8. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1. Diagnosis. Cancer 1993;72:389-393.
9. Bueno R, Reblando J, Glickman J, Jaklitsch MT, Lukanich JM, Sugarbaker DJ. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg 2004;78:1774-1776.
10. Agarwal PP, Seely JM, Matzinger FR, MacRae RM, Peterson RA, Maziak DE, et al. Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy. Radiology 2006;241:589-594.
11. Thylen A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001;92:1224-1230.
12. Baas P. Optimising survival in malignant mesothelioma. Lung Cancer 2007;57(suppl 2):S24-S29.
13. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Chest 1995;108:1122-1128.
14. Edwards JG, Stewart DJ, Martin-Ucar A, Muller S, Richards C, Waller DA. The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma. J Thorac Cardiovasc Surg 2006;131:981-987.
15. Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 1999;172:1039-1047.
16. Truong MT, Marom EM, Erasmus JJ, Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging. J Thorac Imaging 2006;21:146-153.
17. Yamamuro M, Gerbaudo VH, Gill RR, Jacobson FL, Sugarbaker DJ, Hatabu H. Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol 2007;64:356-366.
18. Byrne M, Hillerdal G, Imaging, staging and response evaluation. Lung Cancer 2005;49(suppl 1):S25-S26.
19. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005;49(suppl 1):S27-S32.
20. 18F-FDG PET scans. J Nucl Med 2007;48:1449-1458.
21. Conlon KC, Rusch VW, Gillern S. Laparoscopy: an important tool in the staging of malignant pleural mesothelioma. Ann Surg Oncol 1996;3:489-494.
22. Rice DC, Erasmus JJ, Stevens CW, Vaporciyan AA, Wu JS, Tsao AS, et al. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg 2005;80:1988-1992, discussion 92-3.
23. Martin-Ucar AE, Nakas A, Edwards JG, Waller DA. Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma. Eur J Cardiothorac Surg 2007;31:765-770, discussion 70-1.
24. Alvarez JM, Ha T, Musk W, Robins P, Price R, Byrne MJ. Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy. J Thorac Cardiovasc Surg 2005;130:905-906.
25. Van Ruth S, Baas P, Zoetmulder FA. Surgical treatment of malignant pleural mesothelioma: a review. Chest 2003;123:551-561.
26. Cameron RB. Extrapleural pneumonectomy is the preferred surgical management in the multimodality therapy of pleural mesothelioma: con argument. Ann Surg Oncol 2007;14:1249-1253.
27. Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol 2006;1:175-176.
28. Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2:957-965.
29. Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet 2004;364:1183-1185.
30. Treasure T, Utley M. Ten traps for the unwary in surgical series: a case study in mesothelioma reports. J Thorac Cardiovasc Surg 2007;133:1414-1418.
31. Treasure T, Duffy N, Tan C, Peckitt C, Coombes G. The Mesothelioma and Radical Surgery (MARS) trial update. Lung Cancer 2006;54(suppl 1):44a.
32. Rice D. Reply to Aelony. Ann Thorac Surg 2006;82:233.
33. Aelony Y. Staging in malignant mesothelioma. Ann Thorac Surg 2006;82:2337.
34. Sugarbaker DJ. Editorial comment. Eur J Cardiothorac Surg 2007;31:770-771.
35. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63, discussion 63-5.
36. Rusch VW. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 1997;9:367-372.
37. Soysal O, Karaoglanoglu N, Demiracan S, Topcu S, Tastepe I, Kaya S, et al. Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur J Cardiothorac Surg 1997;11:210-213.
38. Grossebner MW, Arifi AA, Goddard M, Ritchie AJ. Mesothelioma: VATS biopsy and lung mobilization improves diagnosis and palliation. Eur J Cardiothorac Surg 1999;16:619-623.
39. Ceresoli GL, Gridelli C, Santoro A. Multidisciplinary treatment of malignant pleural mesothelioma. Oncologist 2007;12:850-863.
40. Sugarbaker DJ, Strauss GM, Lynch TJ, Richards W, Mentzer SJ, Lee TH, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993;11:1172-1178.
41. Krug LM, Pass H, Rusch VW, Kindler HL, Sugarbaker D, Rosenzweig K, et al. A multicenter U.S. trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT) for stage I-III malignant pleural mesothelioma (MPM). J Clin Oncol 2007;18S:7561.
42. Chang M, Sugarbaker DJ. Technique of extrpleural pneumonectomy for diffuse malignant pleural mesothelioma. In: Shields TW, editor. General thoracic surgery. 6th edition. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 922-929.
43. Argote-Greene LM, Chang MY, Sugarbaker DJ. Extrapleural pneumonectomy for malignant pleural mesothelioma. MMCTS 2005 (http://mmcts._ctsnetjournals.org/ cgi/content/full/2005/0628/mmcts.2004.000133).
44. Sugarbaker DJ, Jaklitsch MT, Bueno R, Richards W, Lukanich J, Mentzer SJ, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004;128:138-146.
45. Opitz I, Kestenholz P, Lardinois D, Muller M, Rousson V, Schneiter D, et al. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006;29:579-584.
46. Flores RM. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer 2005;49(suppl 1):S71-S74.
47. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788-795.
48. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999;17:25-30.
49. Van Haarst JM, Baas P, Manegold C, Schouwink JH, Burgers JA, de Bruin HG, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002;86:342-345.
50. Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004;22:3451-3457.
51. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
52. Rusch VW. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? J Clin Oncol 2003;21:2629-2630.
53. Rice DC, Stevens CW, Correa AM, Vaporciyan AA, Tsao A, Forster KM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007;84:1685-1692, discussion 92-3.
54. Allen AM, Czerminska M, Janne PA, Sugarbaker DJ, Bueno R, Harris JR, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006;65:640-645.
55. Neragi-Miandoab S. Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006;29:14-19.
56. Hasegawa S, Tanaka F, Okada M, Nakano T. Current status of multi-modality treatment for malignant pleural mesothelioma in Japan (in press).
57. Takagi K, Tsuchiya R, Watanabe Y, Surgical approach to pleural diffuse mesothelioma in Japan. Lung Cancer 2001;31:57-65.
58. Higashiyama M, Morinaga K. Survey of surgical treatment of malignant pleural mesothelioma in Japan. Kyobu Geka 2007;60:19-24.
59. Okada M, Mimura T, Ohbayashi C, Sakuma T, Soejima T, Tsubota N. Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact Cardiovasc Thorac Surg 2008;7:102-106.
60. http://www.hyo-med.ac.jp/department/jmrc/.